The infectious disease testing market size was valued at USD 28 billion in 2025 and is projected to grow from USD 30 billion in 2026 to USD 60 billion by 2034 at a CAGR of 7% during the forecast period (2026-2034). North America dominated the infectious disease testing market with a market share of 41.2% in 2025.
Infectious disease testing involves diagnostic methods used to detect bacteria, viruses, fungi, parasites, and other disease-causing pathogens in clinical samples. These tests play a vital role in early diagnosis, disease surveillance, treatment selection, and infection control across healthcare settings. Demand is driven by the rising prevalence of infectious diseases, growing awareness of preventive healthcare, advancements in molecular diagnostics, and increasing investments in public health infrastructure.
Download a Free Sample To learn more about this report,
Growing Adoption of Rapid Molecular Diagnostics and Point-of-Care Testing
Infectious Disease Testing Market trends are being driven by the increasing demand for rapid and accurate diagnostic solutions across hospitals, clinics, and community healthcare settings. Rising cases of respiratory infections, antimicrobial resistance, and emerging viral diseases have encouraged healthcare providers to adopt molecular diagnostics and point-of-care testing for faster clinical decision-making. Advances in multiplex PCR, digital diagnostics, and portable testing platforms are reducing turnaround times while improving diagnostic accuracy. These developments are supporting infectious disease testing market growth by enabling early disease detection and timely treatment.
Rising Investment in AI-Enabled Diagnostics and Automated Laboratory Solutions
Infectious Disease Testing Market trends are also being influenced by growing investments in laboratory automation, artificial intelligence, and integrated diagnostic platforms. Healthcare laboratories are adopting automated sample processing systems and AI-assisted data analysis to improve workflow efficiency, reduce manual errors, and increase testing capacity. These technologies are particularly valuable during periods of high testing demand, allowing laboratories to deliver faster and more consistent results. Such innovations are strengthening infectious disease testing market share as diagnostic companies continue to develop scalable solutions for modern healthcare systems.
Rising Prevalence of Infectious Diseases and Demand for Early Diagnosis
The infectious disease testing market is experiencing strong growth as healthcare systems place greater emphasis on the early detection and effective management of infectious diseases. Increasing cases of respiratory infections, tuberculosis, hepatitis, HIV, sexually transmitted infections, and emerging viral outbreaks are driving the adoption of advanced diagnostic tests. Governments and healthcare organizations are also expanding disease surveillance programs and laboratory infrastructure, further strengthening infectious disease testing market demand. The growing use of molecular diagnostics and rapid testing technologies is helping healthcare providers deliver faster and more accurate diagnoses.
High Cost of Advanced Diagnostic Technologies and Limited Access
The infectious disease testing market faces restraints due to the high cost of advanced molecular diagnostic systems and specialized laboratory equipment. Many healthcare facilities in low- and middle-income countries continue to face budget limitations, restricting access to modern testing technologies. In addition, maintaining sophisticated diagnostic laboratories requires skilled professionals, continuous quality assurance, and regular equipment maintenance, increasing operational costs for healthcare providers.
Expansion of Point-of-Care Testing and Molecular Diagnostics
The infectious disease testing market presents significant opportunities through the growing adoption of point-of-care testing, multiplex molecular diagnostics, and automated laboratory solutions. Healthcare providers are increasingly investing in rapid diagnostic technologies that deliver accurate results within a shorter timeframe, improving patient outcomes and reducing disease transmission. Continued innovation in portable testing devices, digital laboratory systems, and AI-assisted diagnostics is expected to strengthen infectious disease testing market share while expanding access to high-quality testing services.
Keeping Pace with Emerging Pathogens and Evolving Diagnostic Needs
The infectious disease testing market continues to face challenges as new pathogens emerge and diagnostic requirements become increasingly complex. Diagnostic manufacturers and laboratories must continuously develop and validate new testing methods while complying with evolving regulatory standards and maintaining high levels of accuracy. At the same time, healthcare systems must manage growing testing volumes, workforce shortages, and supply chain disruptions without compromising quality or turnaround time. Addressing these challenges requires continuous investment in laboratory infrastructure, advanced technologies, and skilled professionals.
Request Customizationto receive a tailored report.
Kits & Reagents Segment Dominated the Market with 62.8% Share in 2025
The kits & reagents segment dominated the global infectious disease testing market with a 62.8% share in 2025, driven by their widespread use in routine diagnostic testing, disease surveillance, and laboratory screening. Growing demand for rapid, accurate, and high-throughput diagnostic solutions, along with the increasing prevalence of infectious diseases, continues to strengthen the segment's leading position.
The instruments and software segments are witnessing steady growth as healthcare providers and diagnostic laboratories increasingly adopt automated testing platforms and digital diagnostic solutions. Rising investments in laboratory modernization, workflow automation, and data management systems are supporting demand across both segments.
Continuous technological advancements in diagnostic equipment, artificial intelligence-based analytics, and laboratory information management systems are expected to further enhance testing efficiency. The growing emphasis on early disease detection and integrated diagnostic workflows continues to create opportunities for both instruments and software solutions.
Immunodiagnostics Segment Dominated the Market with 44.6% Share in 2025
The immunodiagnostics segment dominated the global infectious disease testing market with a 44.6% share in 2025, supported by its extensive use in detecting bacterial, viral, and parasitic infections through antibody and antigen testing. The technology's rapid turnaround time, high reliability, and widespread availability continue to make it a preferred choice in hospitals and diagnostic laboratories.
The PCR and DNA sequencing & NGS segments are witnessing significant growth as molecular diagnostic techniques become increasingly important for identifying pathogens with greater speed and precision. Expanding applications in outbreak monitoring, antimicrobial resistance testing, and precision diagnostics are driving adoption across both technologies.
Continuous improvements in sequencing platforms, multiplex PCR assays, and genomic surveillance capabilities are expected to further strengthen these segments. Increasing investments in advanced molecular diagnostics are supporting the development of more accurate and comprehensive infectious disease testing solutions.
Hospitals/Clinical Laboratories Segment Dominated the Market with 48.3% Share in 2025
The hospitals/clinical laboratories segment dominated the global infectious disease testing market with a 48.3% share in 2025, driven by the high volume of diagnostic testing performed for infectious diseases in both inpatient and outpatient settings. Increasing patient admissions, expanding laboratory infrastructure, and the need for timely diagnosis continue to support the segment's leading position.
The reference laboratories and physician offices segments are witnessing steady growth as healthcare systems increasingly rely on specialized diagnostic services and point-of-care testing. Rising demand for accurate confirmatory testing, routine disease screening, and decentralized healthcare services is contributing to the expansion of both segments.
The academic/research institutes segment is also growing steadily due to increasing research activities focused on emerging pathogens, vaccine development, and diagnostic innovation. Growing investments in infectious disease research and public health surveillance continue to support demand for advanced testing technologies across research institutions.
Speak to an Analystto discuss market opportunities.
North America infectious disease testing market accounted for 41.2% of the global market, reaching USD 11.54 billion in 2025, and is projected to grow at a CAGR of 7.35% during the forecast period. Strong healthcare infrastructure, increasing demand for rapid diagnostic tests, and rising investments in molecular diagnostics continue to drive regional market growth. Growing awareness of early disease detection and continuous technological advancements are further supporting market expansion.
The U.S. market was valued at USD 9.81 billion in 2025, making it the largest contributor in North America. Rising prevalence of infectious diseases, increasing adoption of advanced diagnostic technologies, and expanding public health initiatives continue to strengthen market growth.
Canada's market reached USD 1.73 billion in 2025. Growing healthcare investments, increasing laboratory testing capacity, and rising demand for accurate diagnostic solutions continue to support steady market expansion.
Europe infectious disease testing market accounted for 27.4% of the global market, reaching USD 7.67 billion in 2025, and is expected to register a CAGR of 6.92% during the forecast period. Increasing government support for disease surveillance, expanding diagnostic laboratories, and growing adoption of advanced testing technologies are driving regional growth. Continuous investments in healthcare infrastructure are also contributing to market development.
Germany's market accounted for USD 2.22 billion in 2025. Strong diagnostic infrastructure, increasing research activities, and rising demand for molecular testing continue to support market growth.
The UK market was valued at USD 1.53 billion in 2025. Growing investments in public health programs, increasing laboratory capacity, and rising demand for rapid diagnostic tests continue to contribute to market expansion.
Asia Pacific infectious disease testing market accounted for 22.6% of the global market, valued at USD 6.33 billion in 2025, and is projected to register a CAGR of 9.48% during the forecast period. Expanding healthcare infrastructure, increasing population, rising awareness of early disease detection, and growing government investments in diagnostic services continue to accelerate regional market growth.
Japan's market generated USD 1.14 billion in 2025. Increasing adoption of advanced diagnostic technologies, expanding healthcare services, and strong focus on disease surveillance continue to support market growth.
China's market accounted for USD 3.29 billion in 2025, representing the largest share within Asia Pacific. Expanding diagnostic manufacturing capacity, growing healthcare expenditure, and increasing demand for rapid infectious disease testing continue to drive market expansion.
Latin America infectious disease testing market accounted for 5.1% of the global market, reaching USD 1.43 billion in 2025, and is projected to grow at a CAGR of 7.76% during the forecast period. Improving healthcare access, increasing government initiatives for disease control, and expanding diagnostic laboratory networks continue to support regional market growth.
Brazil's market reached USD 0.73 billion in 2025. Rising investments in diagnostic services, increasing awareness of infectious disease screening, and expanding healthcare infrastructure continue to create growth opportunities across the country.
Middle East & Africa infectious disease testing market accounted for 3.7% of the global market, totaling USD 1.04 billion in 2025, and is anticipated to grow at a CAGR of 7.21% during the forecast period. Increasing healthcare investments, improving diagnostic capabilities, and growing focus on infectious disease surveillance are supporting regional market growth.
The UAE market was valued at USD 0.37 billion in 2025. Government initiatives to strengthen healthcare infrastructure, increasing adoption of advanced diagnostic technologies, and rising investments in disease monitoring programs continue to drive market growth.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com